计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V127521-10mg |
10mg |
现货 ![]() |
| |
| V127521-25mg |
25mg |
现货 ![]() |
| |
| V127521-50mg |
50mg |
现货 ![]() |
| |
| V127521-100mg |
100mg |
现货 ![]() |
| |
| V127521-500mg |
500mg |
现货 ![]() |
| |
| V127521-1g |
1g |
现货 ![]() |
| |
| V127521-5g |
5g |
现货 ![]() |
|
| 别名 | 维罗非尼 |
|---|---|
| 英文别名 | 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)- | 207SMY3FQT | HMS3265M04 | STK345998 | EX-A053 | GPXBXXGIAQBQNI-UHFFFAOYSA-N | HMS3265N04 | PLX4032 - Vemurafenib | BCP25783 | HSDB 8143 | Q42311 |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Vemurafenib (PLX4032, RG7204) |
| 生化机理 | Vemurafenib 是一种新型的 B-RAFV600E 强效抑制剂,IC50 为 31 nM。体外实验表明,它能杀死黑色素瘤细胞。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 丝氨酸/苏氨酸蛋白激酶 B-raf 抑制剂 |
| 产品介绍 |
Vemurafenib (PLX4032, RG7204)是一种新型有效的B-Raf V600E抑制剂,IC50为31 nM。A novel and potent inhibitor of B-RAFV600E with IC50 of 31 nM. Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf V600E with IC50 of 31 nM. |
| ALogP | 5 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770186 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide |
| INCHI | InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) |
| InChi Key | GPXBXXGIAQBQNI-UHFFFAOYSA-N |
| Canonical SMILES | CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F |
| Isomeric SMILES | CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F |
| PubChem CID | 42611257 |
| 分子量 | 489.92 |
| 溶解性 | Soluble in DMSO (100 mg/mL), and methanol. Insoluble in ethanol, and water |
|---|---|
| 熔点 | 260-262°C |
| 分子量 | 489.900 g/mol |
| XLogP3 | 5.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 489.073 Da |
| 单同位素质量Monoisotopic Mass | 489.073 Da |
| 拓扑极表面积Topological Polar Surface Area | 100.000 Ų |
| 重原子数Heavy Atom Count | 33 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 790.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08, GHS07 |
|---|---|
| 信号词 | Danger |
| 危险声明 |
H373: 通过长时间或反复暴露对器官造成损害 H413: 可能对水生生物造成长期的有害影响 H302: 吞食有害 H350: 可能导致癌症 H361: 怀疑破坏生育力或未出生的孩子 |
| 预防措施声明 |
P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P330: 漱口 P203: 使用前,获取、阅读并遵守所有安全说明。 P301+P317: 如果被吞咽:请寻求医疗帮助。 P318: 如果暴露或担心,请就医。 P319: 如果你感到不适,请寻求医疗帮助。 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| Appearance(V127521) | White to off-white solid |
| NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-10-23 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 24-01-04 | V127521 | |
| 分析证书 | 23-12-21 | V127521 |
| 1. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, 29 (2). [PMID:37234251] [10.1016/j.jmsacl.2023.05.001] |
| 2. Zhou Bin, Sha Shanshan, Tao Juan, Li Jun, Shen Chen, Zhu Jinjin, Tan Lulu, Dong Liyun, Huang Changzheng. (2022) The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma. Scientific Reports, 12 (1): (1-13). [PMID:36513682] [10.1038/s41598-022-24879-y] |
| 3. Lili Zou, Weiping Ding, Yuanyuan Zhang, Shaohui Cheng, Fenfen Li, Renquan Ruan, Pengfei Wei, Bensheng Qiu. (2018) Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. BIOMATERIALS, 182 (1). [PMID:30096444] [10.1016/j.biomaterials.2018.08.013] |
| 1. Fangjun Chen, Wenda Chen, Zhenxin Wang, Yingfei Peng, Beili Wang, Baishen Pan, Wei Guo. (2023) Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma. Journal of Mass Spectrometry and Advances in the Clinical Lab, 29 (2). [PMID:37234251] [10.1016/j.jmsacl.2023.05.001] |
| 2. Zhou Bin, Sha Shanshan, Tao Juan, Li Jun, Shen Chen, Zhu Jinjin, Tan Lulu, Dong Liyun, Huang Changzheng. (2022) The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma. Scientific Reports, 12 (1): (1-13). [PMID:36513682] [10.1038/s41598-022-24879-y] |
| 3. Lili Zou, Weiping Ding, Yuanyuan Zhang, Shaohui Cheng, Fenfen Li, Renquan Ruan, Pengfei Wei, Bensheng Qiu. (2018) Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. BIOMATERIALS, 182 (1). [PMID:30096444] [10.1016/j.biomaterials.2018.08.013] |